.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Post-marketing liver injury reports lead to Tysabri PI update

March 3, 2008

Liver injury warnings added to natalizumab prescribing information.

Reports of markedly elevated serum hepatic enzymes and elevated total bilirubin in patients receiving natalizumab (